Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blocking HIV Before It Can Infect Any Normal Cells

19.12.2001


A fast, sensitive laboratory test that measures the molecular components involved during the critical moment when HIV infects a normal cell has been developed.


The advance was made by researchers in the University of California, San Diego (UCSD) School of Medicine and VA San Diego Healthcare System.

Described in the December 2001 issue of the Journal of Biological Chemistry (JBC), the test makes it possible to study and design new compounds to block the action of these molecular components before HIV can permanently infect a normal cell, causing it to manufacture more virus.

In recognition of the test as "groundbreaking work toward new pharmaceutical strategies to combat the virus that causes AIDS," the GlaxoSmithKline pharmaceutical company awarded UCSD’s Richard Kornbluth, M.D., Ph.D., with a Drug Discovery and Development Award during a professional meeting last week in Chicago.



Kornbluth, who was senior author of the JBC article, is a UCSD associate professor of medicine and a researcher with the VA San Diego Healthcare System.

Kornbluth explains that once HIV enters a host cell’s DNA, the cell becomes permanently infected after the virus splices its genes into the DNA of the host cell, a process known as "integration."

Drugs now available to treat HIV-infected individuals work by inhibiting enzymes that contribute to the spread of HIV, but no drugs have yet been approved that prevent the virus from integrating its DNA into the host cell.

"If we can find a way to intercept HIV during the integration process, when HIV DNA is spliced into normal cells, we can stop it before the cell is permanently infected," Kornbluth says.

HIV drugs now used to treat patients inhibit reverse transcriptase and protease, two of the three enzymes that play a role in infection. Reverse transcriptase works after HIV has entered a host cell by copying the viruses RNA genome into a DNA form. Protease affects the structure of the virus by cutting viral proteins into short pieces that can be incorporated into new viruses.

The third enzyme, integrase, is part of a group of molecules called a preintegration complex (PIC) that promotes HIV integration into the host cell DNA. The entire PIC moves through a pore in the nucleus of the invaded cell, where integrase inserts genes from the viral DNA into the cell’s chromosomes, which is required for the production of more HIV viruses by the infected cell.

The test developed in the Kornbluth lab will allow scientists and drug developers to search millions of chemical compounds for potential drugs that can inhibit any of the components required for the PIC to integrate, not just drugs that inhibit the enzyme integrase.

"The major way that pharmaceutical companies develop drugs is to screen collections of chemicals, anywhere from 100,000 to three million," Kornbluth says. "Our test will allow them to target the entire PIC which is the actual target a successful drug must attack. We believe that molecular components in the PIC, besides integrase, are critical to whether or not HIV is able to integrate into the host cell DNA."

In addition to its ability to look at the entire PIC, Kornbluth’s test is considerably faster than a test developed in 1987, with results taking 2-3 hours rather than 2-3 days. There’s also increased volume: 100 tests can be done in 2-3 hours, compared to about 30 tests that were run over 2-3 days.

With Kornbluth, authors of the article in JBC were Alexei Brooun, Ph.D., a postdoctoral fellow in Kornbluth’s lab, and Douglas R. Richman, M.D., director of the UCSD AIDS Research Institute and professor of medicine and pathology, UCSD and VA San Diego Healthcare System.

The work was funded by the American Foundation for AIDS Research (amfAR), the National Institutes of Health, the State of California’s Universitywide AIDS Research Program, the UCSD Center for AIDS Research, the Department of Veteran Affairs and the Research Center on AIDS and HIV Infection of the VA San Diego Healthcare System.

| International Science News

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>